title: Prognostic factors in patients with esophageal carcinoma treated with chemoradiation: single center experience.
abstract: OBJECTIVE
  The trimodality therapy including chemotherapy, external beam radiation and surgery is widely accepted as the standard of care in patients with locoregional esophageal carcinoma.
  
  
  METHODS
  We have performed a retrospective analysis of patients with locoregional esophageal carcinoma treated with chemoradiation.
  
  
  RESULTS
  One-hundred and fifty-two consecutive patients with non-metastatic adenocarcinoma or squamous cell esophageal carcinoma treated with chemoradiation were included in the present analysis. The median survival of the whole group was 12 months. The estimated 3- and 5-year survival rates were 24% and 19%, respectively. On multivariate analysis, female sex, weight loss and serum albumin were independent negative predictors of survival. Among 140 patients who survived more than 3 months, weight loss, female sex and therapy with paclitaxel were negatively associated with prognosis, and among 109 patients surviving more than 6 months the dose of cisplatin and surgery were independent prognostic factors. Pathologic complete response was not predictive of prognosis.
  
  
  CONCLUSIONS
  Long-term survival is obtained in only about 20% of patients with carcinoma of the esophagus treated with chemoradiation. Female sex, weight loss and low serum albumin are independent indicators of poor prognosis. Among treatment-related factors, higher dose of cisplatin and esophagectomy were independent predictors of better prognosis, while administration of paclitaxel was associated with poor prognosis.
authors.affiliation: Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic.
authors.forename: Jan
authors.initials: J
authors.lastname: Cincibuch
authors.forename: Cestmír
authors.initials: C
authors.lastname: Neoral
authors.forename: René
authors.initials: R
authors.lastname: Aujeský
authors.forename: Vlastislav
authors.initials: V
authors.lastname: Srámek
authors.forename: Petr
authors.initials: P
authors.lastname: Schneiderka
authors.forename: Hana
authors.initials: H
authors.lastname: Studentová
authors.forename: Bohuslav
authors.initials: B
authors.lastname: Melichar
authors.forename: Milan
authors.initials: M
authors.lastname: Kohoutek
authors.forename: Jana
authors.initials: J
authors.lastname: Stráznická
authors.forename: Radek
authors.initials: R
authors.lastname: Vrba
authors.forename: Jarmila
authors.initials: J
authors.lastname: Juránová
authors.forename: Patrik
authors.initials: P
authors.lastname: Flodr
authors.forename: Jindrich
authors.initials: J
authors.lastname: Machácek
authors.forename: Karel
authors.initials: K
authors.lastname: Cwiertha
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000401:mortality / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies